clinical trial · NCT06768671
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Hidradenitis SuppurativaSonelokimab
brief summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
started
Dec 30, 2024
primary completion
Mar 27, 2026
completion
Mar 27, 2026
last updated
Dec 15, 2025
official title
An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol